Endothelin receptor antagonist

Takuya Kishi, Kenji Sunagawa

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Pulmonary arterial hypertension(PAH) is an uncommon disease characterised by a progressive increase in pulmonary vascular resistance. An imbalance between vasoconstrictor/vasodilator activities could be responsible for altered pulmonary vascular tone and structure. In PAH patients, endothelin are increased. Restoration of this imbalance by targeted therapies such as endothelin receptor antagonists should further improve treatment options for the management of PAH. Current treatment algorithms for PAH recommend bosentan as first-line treatment for PAH in functional class III. Recent many trials suggested that endothelin receptor antagonist, bosentan, caused good results in idiopathic PAH and PAH associated with chronic thromboembolism, collagen diseases, and congenital heart diseases.

Original languageEnglish
Pages (from-to)2152-2156
Number of pages5
JournalNippon rinsho. Japanese journal of clinical medicine
Volume66
Issue number11
Publication statusPublished - Jan 1 2008

Fingerprint

Pulmonary Hypertension
Collagen Diseases
Thromboembolism
Endothelins
Vasoconstrictor Agents
Therapeutics
Vasodilator Agents
Vascular Resistance
Blood Vessels
Endothelin Receptor Antagonists
Heart Diseases
Lung

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Kishi, T., & Sunagawa, K. (2008). Endothelin receptor antagonist. Nippon rinsho. Japanese journal of clinical medicine, 66(11), 2152-2156.

Endothelin receptor antagonist. / Kishi, Takuya; Sunagawa, Kenji.

In: Nippon rinsho. Japanese journal of clinical medicine, Vol. 66, No. 11, 01.01.2008, p. 2152-2156.

Research output: Contribution to journalReview article

Kishi, T & Sunagawa, K 2008, 'Endothelin receptor antagonist', Nippon rinsho. Japanese journal of clinical medicine, vol. 66, no. 11, pp. 2152-2156.
Kishi, Takuya ; Sunagawa, Kenji. / Endothelin receptor antagonist. In: Nippon rinsho. Japanese journal of clinical medicine. 2008 ; Vol. 66, No. 11. pp. 2152-2156.
@article{07fd5f1c748d4e6baa9d62a01d4a363b,
title = "Endothelin receptor antagonist",
abstract = "Pulmonary arterial hypertension(PAH) is an uncommon disease characterised by a progressive increase in pulmonary vascular resistance. An imbalance between vasoconstrictor/vasodilator activities could be responsible for altered pulmonary vascular tone and structure. In PAH patients, endothelin are increased. Restoration of this imbalance by targeted therapies such as endothelin receptor antagonists should further improve treatment options for the management of PAH. Current treatment algorithms for PAH recommend bosentan as first-line treatment for PAH in functional class III. Recent many trials suggested that endothelin receptor antagonist, bosentan, caused good results in idiopathic PAH and PAH associated with chronic thromboembolism, collagen diseases, and congenital heart diseases.",
author = "Takuya Kishi and Kenji Sunagawa",
year = "2008",
month = "1",
day = "1",
language = "English",
volume = "66",
pages = "2152--2156",
journal = "Astrophysical Journal",
issn = "0004-637X",
publisher = "IOP Publishing Ltd.",
number = "11",

}

TY - JOUR

T1 - Endothelin receptor antagonist

AU - Kishi, Takuya

AU - Sunagawa, Kenji

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Pulmonary arterial hypertension(PAH) is an uncommon disease characterised by a progressive increase in pulmonary vascular resistance. An imbalance between vasoconstrictor/vasodilator activities could be responsible for altered pulmonary vascular tone and structure. In PAH patients, endothelin are increased. Restoration of this imbalance by targeted therapies such as endothelin receptor antagonists should further improve treatment options for the management of PAH. Current treatment algorithms for PAH recommend bosentan as first-line treatment for PAH in functional class III. Recent many trials suggested that endothelin receptor antagonist, bosentan, caused good results in idiopathic PAH and PAH associated with chronic thromboembolism, collagen diseases, and congenital heart diseases.

AB - Pulmonary arterial hypertension(PAH) is an uncommon disease characterised by a progressive increase in pulmonary vascular resistance. An imbalance between vasoconstrictor/vasodilator activities could be responsible for altered pulmonary vascular tone and structure. In PAH patients, endothelin are increased. Restoration of this imbalance by targeted therapies such as endothelin receptor antagonists should further improve treatment options for the management of PAH. Current treatment algorithms for PAH recommend bosentan as first-line treatment for PAH in functional class III. Recent many trials suggested that endothelin receptor antagonist, bosentan, caused good results in idiopathic PAH and PAH associated with chronic thromboembolism, collagen diseases, and congenital heart diseases.

UR - http://www.scopus.com/inward/record.url?scp=58149457218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149457218&partnerID=8YFLogxK

M3 - Review article

C2 - 19051735

AN - SCOPUS:58149457218

VL - 66

SP - 2152

EP - 2156

JO - Astrophysical Journal

JF - Astrophysical Journal

SN - 0004-637X

IS - 11

ER -